A Deadline is coming up on November 26, 2012 in lawsuit for investors in Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) and NASDAQ:QCOR stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

San Diego, CA -- (SBWire) -- 11/06/2012 --A deadline is coming up on November 26, 2012 in the lawsuit filed for investors of Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) over alleged securities laws violations by Questcor Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements regarding its injectable drug H.P. Acthar Gel.

Investors with a substantial investment in Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) shares between April 26, 2011 and September 21, 2012, should get active before the Deadline that is coming up on November 26, 2012, and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Questcor is a biopharmaceutical company and its primary product is H.P. Acthar Gel (Repository Corticotropin Injection), an injectable drug that is approved by the U. S. Food and Drug Administration (“FDA”) for the treatment of several conditions, including multiple scelorosis, nephrotic syndrome and infantile spasms.

According to the complaint filed in the U.S. District Court for the Central District of California the plaintiff alleges on behalf of purchasers of Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) common stock during the period between April 26, 2011 and September 21, 2012, that Questcor Pharmaceuticals, Inc. and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing between April 26, 2011 and September 21, 2012 allegedly false and misleading statements about the effectiveness of Acthar as a treatment for multiple scelorosis and nephrotic syndrome, making it allegedly impossible for shareholders to gain a meaningful or realistic understanding of the drug’s prospects and market success

On September 24, 2012, Questcor Pharmaceuticals, Inc. disclosed in a filing with the Securities and Exchance Commission that on September 21, 2012, Questcor Pharmaceuticals, Inc. (became aware of a U.S. government investigation involving Questcor Pharmaceuticals’ promotional practices.

Earlier in September 2012 Aetna Inc. said it would limit coverage of Questcor's top-selling drug, H.P. Acthar, a treatment for multiple sclerosis and infant seizures. Aetna issued a Clinical Policy Bulletin stating that based on review of medical studies Acthar was "not medically necessary" for certain conditions for which it has been prescribed and as a result Aetna would limit the coverage of H.P. Acthar.

Shares of Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) dropped from as high as $51.97 per share on September 7, 2012 to as low as $17.83 per share on September 27, 2012.

Those who purchased shares of Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com